PriceTargets.com logo

DMK Pharmaceuticals - DMK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: ∞
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/7/2024 12:59 AM ET
+0 (0.00%)
Get New DMK Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMK

Analyst Price Target is $1.50
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for DMK Pharmaceuticals in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for DMK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in DMK Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2023Maxim GroupInitiated CoverageBuy$1.50Low
(Data available from 4/29/2019 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/29/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/30/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
DMK Pharmaceuticals logo
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.17
Low: $0.04
High: $0.58

52 Week Range

Now: N/A

Volume

24,157,600 shs

Average Volume

1,155,912 shs

Market Capitalization

$2.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of DMK Pharmaceuticals?

The following Wall Street analysts have issued reports on DMK Pharmaceuticals in the last twelve months: Maxim Group.
View the latest analyst ratings for DMK.

What is the current price target for DMK Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for DMK Pharmaceuticals in the last year. Their average twelve-month price target is $1.50. Maxim Group has the highest price target set, predicting DMK will reach $1.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.50 for DMK Pharmaceuticals in the next year.
View the latest price targets for DMK.

What is the current consensus analyst rating for DMK Pharmaceuticals?

DMK Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DMK will outperform the market and that investors should add to their positions of DMK Pharmaceuticals.
View the latest ratings for DMK.

What other companies compete with DMK Pharmaceuticals?

Other companies that are similar to DMK Pharmaceuticals include Salarius Pharmaceuticals, CNS Pharmaceuticals, Dermata Therapeutics, Sonoma Pharmaceuticals and Notable Labs. Learn More about companies similar to DMK Pharmaceuticals.

How do I contact DMK Pharmaceuticals' investor relations team?

DMK Pharmaceuticals' physical mailing address is 11682 El Camino Real, Suite 300, San Diego, CA 92130, United States. The company's listed phone number is 858-997-2400 and its investor relations email address is [email protected]. The official website for DMK Pharmaceuticals is www.dmkpharmaceuticals.com. Learn More about contacing DMK Pharmaceuticals investor relations.